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When drugs are prescribed prophylactically 
or in response to an acute or chronic illness, 
only a portion of the active ingredient of the 
drug is metabolized (Ternes 1998). The non­
metabolized parent compound, as well as the 
metabolites, enter the natural aquatic environ­
ment through waste discharges into receiving 
streams, which may reach downstream rec­
reational lakes or even the intakes of drink­
ing water treatment plants. The ubiquitous 
worldwide use of pharmaceuticals has led to 
the presence of low but measurable part­per­
trillion levels of these biochemically active 
compounds in surface and groundwater. In 
the United States, the most comprehensive 
monitoring of these chemicals in water was 
performed between 1999 and 2000 by the 
U.S. Geological Survey in many of the nation’s 
streams (Kolpin et al. 2002). This study and 
others identified many products, including 
analgesics, antiinflammatories, antibiotics, anti­
epileptics, beta­blockers, blood lipid regulators, 
antidepressants, contrast media, oral contra­
ceptives, and cytostatic and broncho  dilator 
drugs in sewage, surface water, ground  water, 
and drinking water (Costanzo et al. 2005; 
Daughton and Ternes 1999; Glassmeyer et al. 
2008; Heberer 2002; Stackelberg et al. 2007; 
Ternes 1998; Ye et al. 2007).
Pharmaceutical compounds are designed 
to have biochemical activity in target 
organisms at relatively low concentrations. 
Therefore, at the low part­per­trillion levels 
found in aquatic environments, which are far 
below human therapeutic doses, and even 
compared with the much higher levels of rou­
tinely measured water quality chemicals, there 
is concern that some of these compounds 
could have an ecological and human health 
effect. There is, for example, evidence from 
rodent and fish studies that suggests some 
endocrine­disrupting compounds, includ­
ing those found in prescribed synthetic hor­
mones, may contribute to tumor formation 
in humans (Birnbaum and Fenton 2003). The 
identification of pharmaceuticals in surface 
waters has opened a Pandora’s box in a way 
that other discoveries, such as the transmission 
of waterborne infectious diseases, have not. 
This might be because the subject brings to 
light that we may be drinking water that has, 
in part, been recycled through several other 
human bodies. Several countries have turned 
down opportunities to implement waste­
water recycling to supplement potable water 
needs during drought conditions (Casani et al. 
2005; Wilson and Pfaff 2008), but it is hard 
to conceal the fact that many people in those 
countries have been consuming wastewater­
impacted drinking water for many years with­
out any evidence of negative exposure­related 
health outcomes. Nevertheless, the presence 
of pharmaceuticals in surface waters and 
their detection, at much lower levels, in some 
household drinking waters has prompted sig­
nificant public and mass media interest (Donn 
et al. 2008). The potential adverse ecological 
effects and the indirect human exposure to 
pharmaceutical chemicals warrant a multi­
disciplinary evaluation to establish a basis 
for appropriate risk assessment and potential 
environmental impact.
In the United States, the Food and Drug 
Administration (FDA) Center for Drug 
Evaluation and Research requires drug compa­
nies to submit environmental assessments for 
new drug applications (U.S. FDA 2009) with 
predicted wastewater treatment plant (WWTP) 
effluent introductory concentrations of > 1 ppb 
based on high­end projected sales and worse­
case, end­of­pipe effluent discharges. However, 
the U.S. Environmental Protection Agency 
(EPA) is responsible for testing and regulating 
chemicals in drinking water, but pharmaceuti­
cals are not currently regulated. In recognition 
of the growing concerns related to pharmaceu­
ticals, one antibiotic and several hormones used 
in drug formulations are now on the Drinking 
Water Contaminant Candidate List (U.S. EPA 
2010). Clearly, more information is needed to 
guide decisions about whether regulations on 
these chemicals are needed.
In light of these concerns, the Research 
Triangle Environmental Health Collaborative 
organized the Environmental Health Summit 
in the Research Triangle Park of North 
Carolina (USA) in November 2008 to identify 
the major issues surrounding public concern 
with the presence of pharmaceutically active 
chemicals in water. The collaborative was 
established to create a forum to promote part­
nerships and to set research priorities and pub­
lic policy. This summit provided such a forum 
for more than 150 participants from North 
America and beyond, including stakeholders 
from the federal, state, and local govern  ments, 
academic institutions, foundations, nonprofit 
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Ba c k g r o u n d: The presence of pharmaceuticals in aquatic environments and in drinking water 
has prompted significant public interest regarding potential adverse ecological effects and risks to 
human health.
oBjectives: The Environmental Health Summit held in North Carolina, 10–11 November 2008, 
explored the issues associated with the presence and relative risk of trace levels of pharmaceuticals 
in water. More than 150 participants from government organizations and institutions, academia, 
industry, water utilities, and public interest groups participated in discussions aimed at evaluat­
ing the current knowledge on this issue and at identifying research gaps and innovative solution­
oriented recommendations.
discussion: We present different aspects related to the subject that were discussed at the summit, 
including the source, fate, and transport of pharmaceuticals, their exposure effects and poten­
tial risks to human and ecosystems, and the best management practices to address these issues. 
Recommendations placed emphasis on research needs as well as education, communication, preven­
tion, and intervention programs, and other public health solutions and actions.
co n c l u s i o n s: Despite rising concerns about the presence of trace amounts of pharmaceuticals 
in drinking water, little evidence is currently available that associates these chemicals with adverse 
human health risks. In order to prioritize which pharmaceutical chemicals could potentially pose 
the highest risk to consumers and the environment, the summit participants concluded that more 
studies are needed to generate meaningful and accurate data.
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organizations, drug manufacturing companies, 
and water utilities, as well as environmental 
and public health leaders. Thus, the goal of 
the summit was to provide a balanced consid­
eration of this sensitive subject by recognizing 
its complexity and by involving multiple dis­
ciplines to assess all the related issues. During 
the meeting, a series of questions were tabled 
and a framework for a research agenda was 
created and built around the major issues that 
would address the balance of protecting pub­
lic health through drug use while preventing 
unprescribed exposure from environmental 
input. In this article, we present an overview 
of the summit discussions.
Issues
Sources of pollution, fate, and transport. 
Scientific data regarding the source, fate, and 
transport as well as the environmental and 
human impact of veterinary and human phar­
maceuticals would be beneficial to all stake­
holders, including policy makers, to help assure 
that current use and disposal patterns offer no 
threat to society. However, such data as well as 
exposure assessment are limited and uncertain, 
in some cases generating challenges that can 
be considered in two major categories: source 
characterization and exposure assessment.
Source characterization. Pharmaceuticals 
are widely consumed by humans and also used 
in many animal feed commodities for treat­
ment and prevention of disease and to enhance 
feed efficiency and growth. However, discrimi­
nation and apportionment between veteri­
nary animal, agricultural, and human waste, 
whether from domestic or industrial sources, 
are not always clear, particularly because data 
on animal­waste pharmaceuticals are quite 
scarce. In the animal production industry, 
technologies have been developed to remove 
various waste products, including nutrients, 
heavy metals, ammonia, pathogenic bacteria, 
odors, and other parameters that are currently 
regulated by legislative mandates in some U.S. 
states. However, current wastewater treatment 
technologies, including those practiced at 
WWTPs, onsite processes, and even emerging 
animal waste treatments, do not specifically 
target pharmaceuticals for removal, so these 
chemicals are likely to be present at high lev­
els in effluents from these processes (Cabello 
2006; Dolliver and Gupta 2008; Kemper 
2008). In fact, WWTPs are frequently identi­
fied as the main points of discharge of phar­
maceuticals in surface waters (Radjenovic et al. 
2007), but limited studies have been carried 
out to track the effectiveness of unit processes 
at these plants. Conducting such studies has 
become more challenging in part because 
plant managers are concerned that data show­
ing the occurrence of pharmaceuticals in their 
waters could be mis  represented by the media 
(Donn et al. 2008). The use of stable chemical 
indicators of pollution for both veterinary and 
human pharmaceuticals was suggested as a 
relatively easy first step for tracking the fate 
and transport of pollutants from these sources 
without the need to identify every chemical 
present in the mix.
The quantity and quality of existing envi­
ronmental occurrence data for pharmaceuti­
cals are insufficient for decision making and 
may be questionable if the data are generated 
from nonstandardized analytical methods with 
insufficient quality assurance and control. For 
the most part, such data do not account for 
human or environmental metabolites or par­
titioning behavior between the aqueous and 
sediment phases in the natural environment. 
Furthermore, single­grab samples, which are 
the source of much of the data, do not ade­
quately capture variation throughout the day, 
and, when used to measure environmental 
inputs, may not represent the true concentra­
tions. Efforts should be made to choose more 
representative sampling methods that also take 
into account spatial variability (related to land 
and drug use patterns) and temporal variability 
and cycles (including longitudinal changes).
The ability to predict the fate and trans­
port of chemicals in aquatic systems depends 
on the availability of physicochemical data 
that describe, among other characteristics, dis­
tribution coefficients, soil–water partitioning, 
and biodegradation rates. As part of the drug 
approval process in the United States, drug 
manufacturers must generate much of these 
data. If access to such data were improved, sci­
entists would be in a better position to control 
and improve the design of water and WWTP 
technologies. The U.S. EPA is currently 
assembling a knowledge­based inventory 
that includes physical–chemical properties, 
occurrence data, analytical methods, WWTP 
influent and effluent measurements, and a 
bibliographic database for research.
Exposure assessment. Data on pharmaceu­
tical degradation rates will assist in the design 
of models to predict their fate and characteriza­
tion of processes that influence their transport, 
such as those in and between soil and ground­
water or downstream of a point­source dis­
charge. Additional studies on the human and 
ecological risk of pharmaceuticals at environ­
mentally relevant levels, including synergistic 
effects with other chemicals, would be benefi­
cial for an accurate exposure assessment.
Pharmaceuticals represent a class of several 
hundred chemicals that together with their 
human and environmental metabolites pres­
ent a major challenge in terms of developing 
standardized, reliable sampling and analytical 
methods with adequate quality control. Such 
methods could be built around a prioritized 
list that takes into account production and 
use, their predicted “impact” based on toxic­
ity and activity, and their degradation and 
persistence in WWTP effluents; however, a 
critical data review process should be in place 
to ensure methodological credibility and to 
provide a sound basis for source characteriza­
tion and exposure assessment.
The bioconcentration of pharmaceuticals 
in indicator species, such as aquatic life and 
their predators, could provide a better measure 
of environmental loading and accumulation 
because they are closer to sources of pollutants.
Pharmaceutical agents and their human 
metabolites are being discharged into the 
aquatic environment at a loading that is 
related to the size and the age of people in 
the community and the dynamic relationship 
between WWTP discharge and environmental 
exposure. This loading is likely to be affected 
by three major factors: a) the production of a 
more concentrated effluent from WWTPs due 
to the increase in population density and the 
number of elderly people in the community, 
b) the reduced dilution of sewage as a conse­
quence of sustained drought conditions that 
results in a reduced flow of receiving streams 
and an increased proportion of treated waste­
water reaching downstream reservoirs, and 
c) an increase in the number of communities 
moving to the use of reclaimed water because 
of water scarcity and climate change.
Sources of drinking water (both surface 
and ground) are increasingly being affected by 
upstream WWTP discharges or soil–aquifer 
infiltration, but it remains to be demonstrated 
whether the technology used in processing 
wastewater for reclamation is selective in 
removing pharmaceutically active chemicals 
or whether they can be concentrated through 
sediment transport. Evidence to date suggests 
that the simplest and most commonly used 
conventional WWTPs are only partially effec­
tive in removing the most hydrophobic com­
ponents and, in so doing, concentrate a wide 
range of organics, including pharmaceuti­
cals (Chenxi et al. 2008), in biosolids that are 
often sold as fertilizer, which when irrigated 
could release the chemicals into the ground.
Exposure effects and risks to humans and 
ecosystems. When assessing environmental and 
health risks from exposure to chemical pol­
lutants, it is important to clearly distinguish 
between humans and ecosystems in terms 
of both exposure and effects. The effects of 
parts per billion or lower concentrations on 
ecosystems can range from changes in gene 
expression to changes in population structure, 
although little evidence exists for such adverse 
effects from most pharmaceuticals. However, 
two extraordinary examples do exist. The best 
known was the dramatic decrease in vulture 
populations in India and Pakistan (95% in 
3 years), where vultures that fed on carcasses of 
cattle treated with diclofenac died from renal 
failure because they were unable to excrete 
the drug (Oaks et al. 2004). The other case Rodriguez-Mozaz and Weinberg
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involved the deliberate dosing of an entire 
experimental lake with low levels of the active 
ingredient in birth control pills, ethinyl estra­
diol. Within the first year, fathead minnows 
showed evidence of responses at the cellular 
and tissue levels and declines in the popula­
tion; by the second year, the fish population 
had collapsed completely (Kidd et al. 2007). 
Other studies have shown evidence of endo­
crine disruption effects in fish populations 
(e.g., intersex, histological changes in gonads, 
feminization of male fish preventing them from 
reproducing) exposed to effluents that contain 
chemicals such as ethinyl estradiol (Jobling 
et al. 1998); the predicted no­effect concentra­
tion for aquatic effects from this compound is 
< 1 ppt (Caldwell et al. 2008), but levels of this 
chemical have been found at up to 27.4 ppt in 
the river waters of Taiwan (Chen et al. 2007) 
and at up to 178 ppt in WWTP effluents in 
Australia (Fernandez et al. 2007).
In aquatic ecosystems, the fact that many 
of these chemicals are designed to resist bio­
degradation favors their adsorption onto 
watershed sediments, so despite the low aque­
ous levels reported, we do not yet have a grasp 
of the implications of their constant infu­
sion into rivers and streams. Could this, for 
example, be generating a hidden environmen­
tal risk associated with long­term exposure 
and combinatory effects? The case of anti­
biotics could be enlightening; for example, 
a study in North Carolina (USA) has sug­
gested that a defined environmental effect, 
the development of antibiotic resistance, may 
be evolving in the aquatic–sediment interface 
where multiple antibiotics are accumulating 
(Stauffenberg and Weinberg 2006).
The primary exposure pathways to humans 
other than those from prescribed dosing are 
through drinking water at part­per­trillion 
levels (Stackelberg et al. 2007; Ye et al. 2007), 
which for typical daily consumption over a 
lifetime, would provide exposure to individual 
compounds well below a single therapeutic 
dose and suggest little threat to human health 
(Fent et al. 2006), although the effects on 
pregnant women and their fetuses are still 
not clear. Exposure through bathing in con­
taminated recreational waters, the potential 
for pharmaceuticals to migrate across the skin 
barrier, and contact with antibiotic­resistant 
bacteria are all potential secondary exposure 
pathways and examples of research needs for 
assessing the impact of pharmaceuticals in the 
environment (Ankley et al. 2007).
Approaches to the evaluation of toxicity 
associated with chronic low­dose exposure to 
mixtures of pharmaceuticals vary depending 
on whether we consider human or ecological 
hazard risk assessment. As an example, surveil­
lance of waters receiving wastewater effluents 
is critical for ecological hazard risk assessment, 
whereas biomonitoring or chemical analysis of 
drinking water is more important for human 
hazard risk assessment. However, it is criti­
cal to ensure that the correct end points are 
being considered and that they are plausible 
to measure in low­dose chronic exposures. 
There is, therefore, a need to consider non­
traditional end points of toxicity, such as 
behavioral, developmental, and reproductive 
responses, including toxicogenomics, relevant 
“omics” techniques in general, or others such 
as “no observable transcriptional effect levels.” 
A need also exists to identify organisms or 
subsets of populations, including specific life 
stages (e.g., fetal development), that might be 
more vulnerable to pharmaceuticals. In partic­
ular, assessment of pharmaceuticals must con­
sider the mixture of compounds with which 
exposure occurs. The assumption that addi­
tive models do not adequately assess effects 
of pharmaceuticals has not been rigorously 
tested, so the applicability of existing screen­
ing methods must be evaluated. Alternate 
ways to address or evaluate mixtures can be 
considered, including a screening­threshold 
approach where the threshold of toxicologic 
concern is the denominator (Daughton 2008; 
Kroes et al. 2005), the measured or predicted 
exposure concentration is the numerator, and 
the resulting ratio is evaluated: If < 1, no fur­
ther actions are warranted. Alternatively, an 
integrated epidemiological, biomonitoring, 
and demographic approach could be used. In 
fact, such an approach was recently applied 
to the assessment of a different category of 
drinking water contaminants, namely, mix­
tures of disinfection by­products that were 
formed during the treatment of drinking 
water (Simmons et al. 2008). That study 
could serve as a model to frame the evaluation 
of mixtures of pharmaceuticals.
Risk assessment could also benefit from 
a prioritization listing of pharmaceuticals to 
help determine which pose the highest risk 
based on specific factors such as mode of 
action, therapeutic dose, and environmen­
tal exposure. Kostich and Lazorchak (2008) 
recently published a model to help implement 
this pharmaceutical prioritization approach, 
but no widely accepted prioritization list yet 
exists. It would also be prudent to test whether 
the existing human health data on pharma­
ceuticals can be applied to environmental 
hazard risk assessment even when the envi­
ronmental doses are much lower than thera­
peutic doses. Ecosystem adaptation and the 
changes in sensitivity of organisms (increased 
or decreased) with continuous exposure are 
other critical issues to be considered in future 
health and ecological risk studies.
Best management practices. Despite the 
various complex variables that combine to 
cause pollution of the aquatic environment 
by pharmaceuticals, actions can be taken to 
reduce their presence in the environment, 
such as responsible disposal of leftover drugs 
from the consumer sector. Some activities have 
already been sponsored by the U.S. federal gov­
ernment regarding drug disposal (Daughton 
2003). As an example, the White House Office 
of National Drug Control Policy, in collabo­
ration with the U.S. EPA and FDA, imple­
mented the nation’s first public guidance on 
consumer drug disposal (Office of National 
Drug Control Policy 2009), but guideline 
standardization is still needed.
The most effective best management prac­
tices (BMPs) would address source reduction, 
namely, reducing the amount of medicine that 
goes unused. The Pharmaceutical Research 
and Manufacturers of America have evaluated 
unused medicine disposal options and have 
concluded that toilet flushing of unused medi­
cine should be avoided whereas household 
trash disposal and take­back programs are effec­
tive at removing the unused medicine contri­
bution to pharmaceuticals in water (SMARXT 
DISPOSAL 2009). Another approach for 
a more environmentally sound handling of 
unused drugs is to use “social marketing” 
(Newton­Ward 2007). Marketing technologies 
would be applied to the analysis, planning, exe­
cution, and evaluation of programs designed to 
influence the voluntary behavior of target audi­
ences toward drug disposal.
Before implementation of BMPs can be 
assured and widely practiced, the following 
questions need to be addressed: 
•	What	are	the	roles	and	responsibilities	of	
players within the various interconnected 
domains, namely, the industrial, medical, 
social, and environmental sectors? 
•	Which	metrics	should	be	used	to	design	
and assess BMPs; are they currently being 
deployed, and how predictive are they? 
•	What	achievable	BMPs	can	be	established	
for contaminants already known to cause 
adverse effects? 
•	What	can	be	done	immediately	with	what	
we know today, and which BMPs are prac­
tical and cost­effective to implement?
Responses to these questions will dif­
fer depending on the sector considered. 
Supplemental Material, Table 1 (available 
online at doi:10.1289/ehp.0901532) suggests 
the most feasible BMPs for short­term imple­
mentation, which are presented in order of 
priority according to such criteria as speed 
of implementation, cost containment, and 
efficacy.
The production, transport, and fate of 
pharmaceuticals cross the jurisdiction of mul­
tiple regulatory agencies in the United States, 
creating a challenge to balance the societal 
need for safe and effective drugs against pos­
sible deleterious human and environmental 
impacts from the presence of their residues 
in the environment. Better interagency coop­
eration, data sharing, a focal point for Pharmaceuticals in water: an interdisciplinary approach
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communication, and overall better federal 
facilitation are essential to seriously address 
public concerns on these issues, which include 
the judicious evaluation and effective solv­
ing of any questions or problems that arise. 
During summit discussions, a consensus was 
reached that some organization (which, in 
the United States, could be the U.S. EPA or 
another federal agency) needs to oversee the 
specific issue of pharmaceuticals in drinking 
water to ensure justification for action or lack 
thereof. The U.S. Congress might designate 
leadership to provide guidance and back­
ground on existing efforts, but stakeholders 
have to be involved in the evolution of pro­
cess, and these should include at a minimum 
with pharmaceutical companies, water utili­
ties, regulatory agencies, and academia.
Education and communication. Three key 
areas were suggested for education and com­
munication: transparency, research into com­
munication, and focus of education.
Transparency. The implications of the 
presence of pharmaceuticals in water should 
be communicated to the public in a truthful 
manner without raising alarm or suspicion 
and causing mistrust.
Research into communication. The tar­
get audience has to be identified, as well as 
their perception of the subject before com­
muniqués are distributed. Potential audiences 
would include the general public, legislators, 
farmers, regulators, health and food industry 
representatives, water treatment plant and 
WWTP operators, journalists, and scientists.
Focus of education. Those who prescribe 
and dispense medications, farmers, and the 
general public should be educated with the 
objective of creating interventions with the 
most likely and immediate impact.
Supplemental Material, Table 2 (doi:10. 
1289/ehp.0901532) provides initial recom­
mendations for better communication and 
education, prioritized in terms of feasibility 
for short­term implementation.
One specific goal established during the 
summit was to come up with a simple and 
transparent response to public and media con­
cerns about the safety of the drinking water 
supply related to pharmaceutical contamina­
tion. In response to this task, the summit par­
ticipants issued the following statement:
“If your drinking water meets current U.S. 
standards, your drinking water is considered safe 
and drinkable. We recognize that trace amounts 
of pharmaceuticals in combination with other 
chemicals have been found in water. These sub­
stances are coming from a variety of sources and 
are difficult to completely remove. There is lim­
ited information on how long­term, low­dose 
exposures affect humans and wildlife. U.S. stan­
dards may need to be developed for pharma­
ceutical compounds in drinking water or in 
aquatic systems as more information becomes 
available.” (Research Triangle Environmental 
Health Collaborative 2008).
Although not wishing to convey a false 
sense of security to the public by declaring 
the water supply risk­free from the effects of 
pharmaceuticals, it is important to stress that 
risk assessment is ongoing. Moreover, even 
if it turns out that pharmaceuticals are not 
a major concern, there are still other chemi­
cals (e.g., personal care products, pesticides, 
industrial contaminants, etc.) that could pose 
a human health or ecological risk.
Conclusions and 
Recommendations
Despite rising fears over the presence of phar­
maceuticals in drinking water, there is currently 
little evidence associating them with adverse 
human health risks, but this summit served 
to highlight the issues of concern that need 
to be addressed to confirm this perception. 
Supplemental Material, Table 3 (doi:10.1289/
ehp.0901532) collates the major research needs 
in this respect. For example, more and better 
data are needed to prioritize which pharmaceu­
tical chemicals could potentially pose the high­
est risk to consumers and to the environment. 
The identification of those drugs susceptible to 
formation of degradation and/or transforma­
tion products that have equal or more toxicity 
than the parent compounds is a critical point 
in this respect. Effectiveness of current waste­
water treatment, on­site processes, and emerg­
ing animal waste treatment technologies also 
needs to be evaluated.
In general, ecosystems appear to be more 
at risk than humans in part because aquatic 
organisms may have a higher sensitivity to 
and may be exposed to higher levels of phar­
maceutical residues than are humans. The key 
challenge in assessing the risk of pharmaceuti­
cals in the environment is to evaluate whether 
unintended long­term, low­dose exposures to 
mixtures of these chemicals can potentially 
affect humans and wildlife. In this respect, 
questions regarding susceptible subpopulations 
or life­stage sensitivity (e.g., the fetus) must be 
considered. Existing frameworks, such as those 
developed for pesticides and disinfection by­
products, including the use of tracers or sur­
rogates for whole groups of pollutants, may be 
appropriate for use as models assessing hazard 
or risk of pharmaceuticals in the environment.
BMPs have to be implemented covering the 
industrial, medical and veterinary, social and 
agricultural, and environmental spheres. Most 
BMPs suggested in this review focus on educa­
tion of the health care community and general 
public on the proper disposal of unused medi­
cine and how steps can be taken to reduce the 
amount of medicine that goes unused. Other 
BMPs listed include take­back programs, evalu­
ation of treatment technologies, and increased 
monitoring of pharmaceuticals in water. An 
evaluation of the effectiveness of BMPs once 
they have been implemented would be desir­
able, but there needs to be supervision or over­
sight for coordination of all activities related to 
studying the specific issue of pharmaceuticals in 
drinking water and their sources.
Even though there is limited information 
about environmental and public health effects 
derived from the presence of pharmaceuticals 
in water, there is a need to communicate what 
is known. The use of new technologies is rec­
ommended for facilitating communication and 
collaboration. However, the information must 
be clear, without providing mixed messages on 
the subject of potential yet currently unknown 
risks, remaining truthful without causing 
alarm. If the idea that water can be considered 
safe is communicated to the public, it must be 
emphasized that this is based on the test data 
of scientific studies, lack of observed adverse 
effects where these have been evaluated, and 
current regulations.
Water scarcity, climate change, aging 
and increasing population density, increasing 
use of pharmaceutical products, and rising 
dependence on water reuse may lead to an 
increase in the presence of pharmaceuticals 
in groundwater, surface water, and drinking 
water in the near future that might pose a risk 
to water safety or an exacerbation of perceived 
risk. Scientific techniques to understand and 
predict the potential for long­term effects of 
pharmaceutical residues in the environment 
are continuing to be developed to assess these 
challenges and to help prevent environmental 
and human health effects.
The summit provided an interdisciplin­
ary forum that considered a multipronged 
approach to a potential public health chal­
lenge. It demonstrated the benefit of collecting 
voices from those who would normally work 
in disconnected environments and provides 
a “clearinghouse” or umbrella through which 
congressional offices and other interested parties 
can seek information on the subject discussed. 
More such interactions among scientists, public 
advocacy groups, and representatives from rel­
evant industries, other stakeholders, and policy 
makers will help to clearly define the challenges 
faced by special issues and to provide each sec­
tor with a better understanding on how best to 
assimilate and disseminate their knowledge. In 
turn, this will help scientists to better advocate 
for public policies.
RefeRences
Ankley GT, Brooks BW, Huggett DB, Sumpter JP. 2007. 
Repeating history: pharmaceuticals in the environment. 
Environ Sci Technol 41:8211–8217.
Birnbaum LS, Fenton SE. 2003. Cancer and developmental 
exposure  to  endocrine  disruptors.  Environ  Health 
Perspect 111:389–394.
Cabello FC. 2006. Heavy use of prophylactic antibiotics in aqua-
culture: a growing problem for human and animal health and 
for the environment. Environ Microbiol 8:1137–1144.Rodriguez-Mozaz and Weinberg
1020  v o l u m e  118 | n u m b e r 7 | July 2010  •  Environmental Health Perspectives
Caldwell D, Mastrocco F, Hutchinson T, Laenge R, Heijerick 
D, Janssen C, et al. 2008. Derivation of an aquatic pre-
dicted no-effect concentration for the synthetic hormone, 
17α-ethinyl estradiol. Environ Sci Technol 42:7046–7054.
Casani S, Rouhany M, Knøchel S. 2005. A discussion paper on 
challenges and limitations to water reuse and hygiene in 
the food industry. Water Res 39:1134–1146.
Chen C-Y, Wen T-Y, Wang G-S, Cheng H-W, Lin Y-H, Lien GW. 
2007. Determining estrogenic steroids in Taipei waters and 
removal in drinking water treatment using high-flow solid-
phase extraction and liquid chromatography/tandem mass 
spectrometry. Sci Total Environ 378:352–365.
Chenxi W, Spongberg A, Witter JD. 2008. Determination of the 
persistence of pharmaceuticals in biosolids using liquid-
chromatography tandem mass spectrometry. Chemosphere 
73:511–518.
Costanzo S, Murby J, Bates J. 2005. Ecosystem response to 
antibiotics entering the aquatic environment. Mar Pollut 
Bull 51:218–223.
Daughton CG. 2003. Cradle-to-cradle stewardship of drugs for 
minimizing their environmental disposition while promoting 
human health. I. Rationale for and avenues toward a green 
pharmacy. Environ Health Perspect 111:775–785.
Daughton CG. 2008. Pharmaceuticals as environmental pollut-
ants: the ramifications for human exposure. In: International 
Encyclopedia of Public Health. Vol 5. (Heggenhougen K, 
Quah S (eds.). Oxford:Academic Press, 66–102. 
Daughton CG, Ternes TA. 1999. Pharmaceuticals and per-
sonal care products in the environment: agents of subtle 
change? Environ Health Perspect 107(suppl 6):907–938.
Dolliver H, Gupta S. 2008. Antibiotic losses in leaching and 
surface runoff from manure-amended agricultural land. 
J Environ Qual 37:1227–1237.
Donn J, Mendoza M, Pritchard J. 2008. AP: drugs found in 
drinking water. Available: http://www.usatoday.com/news/
nation/2008-03-10-drugs-tap-water_N.htm [accessed 
26 August 2009].
Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human 
pharmaceuticals. Aquat Toxicol 76:122–159.
Fernandez MP, Ikonomou MG, Buchanan I. 2007. An assess-
ment of estrogenic organic contaminants in Canadian 
wastewaters. Sci Total Environ 373:250–269.
Glassmeyer  S,  Koplin  D,  Furlong  E,  Focazio  M.  2008. 
Environmental presence and persistence of pharma-
ceuticals: an overview. In: Fate of Pharmaceuticals in the 
Environment and in Water Treatment Systems (Aga DS, ed). 
Boca Raton, FL:CRC Press, Taylor and Francis Books 3–51.
Heberer T. 2002. Occurrence, fate, and removal of pharma-
ceutical residues in the aquatic environment: a review of 
recent research data. Toxicol Lett 131:5–17.
Jobling S, Nolan M, Tyler CR, Brighty G, Sumpter JP. 1998. 
Widespread sexual disruption in wild fish. Environ Sci 
Technol 32:2498–2506.
Kemper N. 2008. Veterinary antibiotics in the aquatic and 
terrestrial environment. Ecol Indic 8:1; doi:10.1016/j.
ecolind.2007.06.002 [Online 19 July 2007].
Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, 
Lazorchak JM, et al. 2007. Collapse of a fish population 
after exposure to a synthetic estrogen. Proc Nat Acad Sci 
USA 104:8897–8901.
Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, 
Barber LB, et al. 2002. Pharmaceuticals, hormones, and 
other organic wastewater contaminants in U.S. streams, 
1999–2000: a national reconnaissance. Environ Sci Technol 
36:1202–1211.
Kostich MS, Lazorchak JM. 2008. Risks to aquatic organisms 
posed by human pharmaceutical use. Sci Total Environ 
389:329–339.
Kroes R, Kleiner J, Renwick A. 2005. The threshold of toxico-
logical concern concept in risk assessment. Toxicol Sci 
86:226–230.
Newton-Ward M. 2007. Appendix: social marketing resources. 
In: Social Marketing: Influencing Behaviors for Good 
(Kotler P, Lee N, eds). Thousand Oaks, CA:Sage, 395–402.
Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, 
Rideout BA, et al. 2004. Diclofenac residues as the cause of 
vulture population decline in Pakistan. Nature 427:630–633.
Office of National Drug Control Policy. 2009. Proper Disposal of 
Prescription Drugs. Available: http://whitehousedrugpolicy.
gov/publications/pdf/prescrip_disposal.pdf [accessed 
11 June 2010]. 
Radjenovic J, Petrovic M, Barceló D. 2007. Analysis of pharma-
ceuticals in wastewater and removal using a membrane 
bioreactor. Anal Bioanal Chem 387:1365–1377.
Research Triangle Environmental Health Collaborative. 2008. 2008 
Summit: Pharmaceuticals in Water. Summit Recommendation 
Document. Available: http://environmentalhealthcollaborative.
org/summit/pharmaceuticals-in-water-summit/ [accessed 
27 May 2010].
Simmons JE, Richardson SD, Teuschler LK, Miltner RJ, Speth TF, 
Schenck KM, et al. 2008. Research issues underlying the 
four-lab study: Integrated disinfection by-products mixtures 
research. J Toxicol Environ Health 71:1125–1132.
SMARXT DISPOSAL. 2009. Available: http://www.smarxtdisposal.
net/resources/Brochure/USFWS-12080_Brochure_FINAL.
pdf [accessed 11 June 2010].
Stackelberg PE, Gibs J, Furlong ET, Meyer MT, Zaugg SD, 
Lippincott RL. 2007. Efficiency of conventional drinking-water-
treatment processes in removal of pharmaceuticals and 
other organic compounds. Sci Total Environ 377:255–272.
Stauffenberg K, Weinberg HS. 2006. Preparing the Framework 
for Evaluating Microbial Resistance in Surface Waters 
and Sediments. Available: http://www.ncsu.edu/wrri/
conference/2006ac/pdf/Stauffenberg.pdf [accessed 
26 May 2010].
Ternes TA. 1998. Occurrence of drugs in German sewage treat-
ment plants and rivers. Water Res 32:3245–3268.
U.S. EPA (U.S. Environmental Protection Agency). 2010. Drinking 
Water Contaminant Candidate List. Available: http://www.
epa.gov/safewater/ccl/ccl3.html [accessed 11 June 2010]. 
U.S. FDA (Food and Drug Administration). 2009. CFR—Code 
of Federal Regulations Title 21. 21CFR25.21. Available: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?fr=25.21 [accessed 19 May 2010].
Wilson Z, Pfaff B. 2008. Religious, philosophical and environ-
mentalist perspectives on potable wastewater reuse in 
Durban, South Africa. Desalination 228:1–9; doi:10.1016/j.
desal.2007.07.022 [Online 18 June 2008].
Ye Z, Weinberg HS, Meyer MT. 2007. Trace analysis of 
trimethoprim and sulfonamide, macrolide, quinolone, and 
tetracycline antibiotics in chlorinated drinking water using 
liquid chromatography electrospray tandem mass spec-
trometry. Anal Chem 79:1135–1144.